
A close-up of hands holding a tablet and a pen

Description automatically generated**U.S. Cancer Immunotherapy Market**

According to Intelli, the U.S. Cancer Immunotherapy Market size was valued at USD 53,302 Million in 2024 and is projected to reach USD 91,918.95 Million by 2032, growing at a CAGR of 7.75% from 2025 to 2032.



Cancer immunotherapy, a groundbreaking approach, represents a revolutionary strategy that empowers the body’s immune system to recognize, target, and destroy cancer cells. Unlike conventional treatments that often harm healthy tissues, immunotherapy enhances the immune system’s natural ability to target cancer specifically and sustainably. According to the American Cancer Society, the United States recorded over 1.8 million new cancer cases and 606,520 cancer-related deaths in 2020. Immunotherapy is being used to treat a growing number of cancers including Melanoma, Non-small cell lung cancer, Renal cell carcinoma, Hodgkin lymphoma etc. However, the effectiveness of immunotherapy often depends on tumor characteristics such as PD-L1 expression, tumor mutation burden and genetic markers. From immune checkpoint inhibitors to CAR T-cell therapy, these innovations have already transformed outcomes for patients with previously untreatable cancers through providing the potential for long-lasting remission with fewer side effects than conventional methods such as chemotherapy and radiation.

**U.S. Cancer Immunotherapy Market definition**

The U.S. cancer immunotherapy market refers to the sector within the American healthcare and pharmaceutical industry that focuses on the research, development, manufacturing, and commercialization of immunotherapy-based treatments for cancer. The U.S. remains one of the largest and most innovative markets globally for cancer immunotherapy. Additionally, increasing investment in clinical trials and drug development and a wave of strategic initiatives by key industry players are expected to drive significant market expansion throughout the forecast period.

**U.S. Cancer Immunotherapy Market Overview**

Innovation serves as the driving force behind growth in the market. Driven by technological advancements, rising cancer prevalence, and increasing demand for targeted and less toxic therapies, the U.S. cancer immunotherapy market is one of the fastest-growing segments in oncology. This market encompasses a range of treatment modalities, including Immune checkpoint inhibitors (e.g., PD-1/PD-L1, CTLA-4 inhibitors), Cancer vaccines, Monoclonal antibodies, Oncolytic virus therapies, CAR T-cell therapies. Drugs like nivolumab, pembrolizumab, and atezolizumab are now considered standard of care for several cancers including NSCLC, melanoma, and bladder cancer. According to data from the American Cancer Society and recent market analysis, the number of patients receiving immunotherapy has tripled over the past decade, and the trend is expected to continue as new therapies receive approval and biomarker testing becomes more widespread.

**U.S. Cancer Immunotherapy Market Segmentation Analysis**

The U.S. Cancer Immunotherapy Market is segmented based on cancer type, therapy type, end-user, and distribution channel.

**U.S. Cancer Immunotherapy Market, By cancer type**

* **Melanoma**
* **Lung Cancer**
* **Breast Cancer**
* **Colorectal Cancer (MSI-H/dMMR)**
* **Bladder Cancer**
* **Renal cell carcinoma**
* **others**

Segmenting the U.S. cancer immunotherapy market by cancer type reveals the vast and expanding reach of these groundbreaking therapies across a wide spectrum of malignancies. Lung cancer, a deadly disease, has seen a paradigm shift with the integration of immune checkpoint inhibitors, dramatically improving survival rates.

In case of colorectal cancer with microsatellite instability, immunotherapy is opening new frontiers where few options previously existed. Additionally, Melanoma, once considered one of the most difficult cancers to treat in advanced stages, is now one of immunotherapy’s greatest success stories. Furthermore, bladder and renal cell carcinoma have also shown strong responses to immunotherapy. It can be transformative force across both solid tumors and hematological cancers.

**U.S. Cancer Immunotherapy Market, By therapy type**

* **Monoclonal Antibodies**
* A close-up of hands holding a tablet and a pen

  Description automatically generatedChimeric monoclonal antibodies
* A close-up of hands holding a tablet and a pen

  Description automatically generatedHumanized monoclonal antibodies
* **Immune Checkpoint Inhibitors**
* PD-1 inhibitors
* PD-L1 Inhibitors
* CTLA-4 Inhibitors
* **Adoptive Cell Therapy**
* CAR-T cell therapy
* TCR therapy
* NK cell therapy
* **Immunomodulators**
* Cytokines
* Oncolytic Viruses
* TLR agonists
* **Cancer Vaccines**
* Preventive cancer vaccines
* Therapeutic cancer vaccines

The U.S. cancer immunotherapy market, segmented by therapy type, highlights a robust pipeline of advanced modalities that are reshaping cancer care. Monoclonal antibodies (Rituximab, Trastuzumab) offer precise action against tumor antigens with minimal impact on healthy tissue. PD-1, PD-L1, and CTLA-4 inhibitors have revolutionized the treatment of various cancers by unleashing the immune system’s ability to recognize and attack cancer cells. Moreover, Adoptive cell therapy represents the frontier of personalized medicine with remarkable efficacy in hematologic cancers. By genetically engineering a patient’s own T cells to express receptors that recognize specific antigens on cancer cells, CAR-T cell therapy empowers the immune system to seek out and destroy malignant cells with remarkable precision. Initially approved for certain blood cancers such as acute lymphoblastic leukemia and diffuse large B-cell lymphoma, CAR-T therapies have shown impressive remission rates in patients who had exhausted conventional options. Meanwhile, cancer vaccines, especially preventive vaccines, are playing a crucial role in reducing cancer incidence by priming the immune system before disease onset. This diverse therapeutic portfolio not only signifies the maturity of the market but also underscores its vast potential for future expansion as next-generation immunotherapies advance and enter the clinical landscape.

**U.S. Cancer Immunotherapy Market, By End-User**

* **Hospitals**
* **Specialty clinics & oncology Centers**
* A close-up of hands holding a tablet and a pen

  Description automatically generated**Cancer Research Institute**

Segmentation of the U.S. cancer immunotherapy market by end-user reflects the widespread adoption of advanced therapies across various healthcare settings. Hospitals remain the dominant end-user segment, driven by their ability to administer complex treatments. Specialty clinics and oncology centers are gaining traction due to their focus on outpatient care, personalized treatment plans, and accessibility for a broader patient population. Cancer research institutes are crucial in pioneering clinical trials and accelerating the development of next-generation immunotherapies.

**U.S. Cancer Immunotherapy Market, By Distribution Channel**

* **Hospital Pharmacies**
* **Retail Pharmacies**
* **Online Pharmacies**

Based on the Distribution Channel, the market is divided into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies. Hospital pharmacies are essential for managing complex drug regimens and ensuring patient safety during treatment. Retail Pharmacies serve a smaller, but growing share of the market, particularly for oral immunomodulators and supportive care medications. Online pharmacies are an emerging distribution channel, offering increased convenience and accessibility to select immunotherapy related drugs and services that particularly beneficial for patients in remote location.

**Key Players**

The “U.S. Cancer Immunotherapy Market" study report will provide valuable insight emphasizing the U.S. market. The major players in the market are Amgen Inc., Bayer AG, Bristol-Myers Squibb, Eli Lilly and Company, F. hoffman La Roche Ltd., Pfizer Inc., Novartis AG, Johnson & Johnson services, AstraZeneca, Merck & Co., AbbVie, Regeneron Pharmaceuticals, Sanofi, Immunocore, Adaptimmune Therapeutics, among others. Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.

A close-up of hands holding a tablet and a pen

Description automatically generated

**Key Developments**

* In 2025, Researchers in the U.S. have developed a groundbreaking test capable of detecting 18 types of early-stage cancers through a simple blood analysis. Developed by Novelna, the test analyzes specific blood proteins, offering a less invasive and more cost-effective alternative to traditional diagnostic methods.
* In December, 2024 Astrazenca’s immunotherapy drug named Imfinzi made a significant breakthrough as it is the first and only approved treatment regimen for limited-stage small cell lung cancer.
* In September, 2024, the FDA granted approval to Tecentriq Hybreza, the first subcutaneous PD-L1 Inhibitor.
* In May, 2024, Amgen announced that the U.S. FDA had approved its immunotherapy, IIMDELLTRA, for the treatment of adult patients with extensive-stage small cell lung cancer**.**

**Market Attractiveness**

The image of market attractiveness provided further helps to get information about the region leading in the U.S. cancer immunotherapy Market. We cover the major impacting factors driving the industry growth in the given region.

**Porter’s Five Forces**

The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. Porter's five forces model can be used to assess the competitive landscape in the U.S. Cancer Immunotherapy Market, gauge the attractiveness of a particular sector, and assess investment possibilities.

A close-up of hands holding a tablet and a pen

Description automatically generated

TABLE OF CONTENT

**1 INTRODUCTION OF U.S. CANCER IMMUNOTHERAPY MARKET**

1.1 Overview of the Market

1.2Scope of Report

* 1. Assumptions

1. **EXECUTIVE SUMMARY**
2. **RESEARCH METHODOLOGY**

3.1Data Mining

3.2Validation

3.3Primary Interviews

* 1. List of Data Sources

**4 U.S. CANCER IMMUNOTHERAPY MARKET** **OUTLOOK**

4.1Overview

4.2Market Dynamics

### 4.2.1 Drivers

### 4.2.2 Restraints

### 4.2.3 Opportunities

### Trends

4.3 Porters Five Force Model

4.4Value Chain Analysis

A close-up of hands holding a tablet and a pen

Description automatically generated5 **U.S. CANCER IMMUNOTHERAPY MARKET, BY CANCER TYPE**

5.1 Overview

5.2 Melanoma

5.3 Lung Cancer

5.4 Breast Cancer

5.5 Colorectal Cancer (MSI-H/dMMR)

5.6 Bladder Cancer

5.7 Renal cell carcinoma

* 1. Others

**6 U.S. CANCER IMMUNOTHERAPY MARKET, BY THERAPY TYPE**

6.1 Overview

6.2 Monoclonal Antibodies

6.2.1 Chimeric monoclonal antibodies

6.2.2 Humanized monoclonal antibodies

6.3 Immune Checkpoint Inhibitors

6.3.1 PD-1 inhibitors

6.3.2 PD-L1 Inhibitors

6.3.3 CTLA-4 Inhibitors

6.4 Adoptive Cell Therapy

6.4.1 CAR-T cell therapy

6.4.2 TCR therapy

* + 1. NK cell therapy

6.5 Immunomodulators

* + 1. Cytokines
    2. Oncolytic Viruses
    3. A close-up of hands holding a tablet and a pen

       Description automatically generatedTLR agonists
  1. Cancer Vaccines
     1. Preventive cancer vaccines
     2. Therapeutic cancer vaccines

1. **U.S. CANCER IMMUNOTHERAPY MARKET, BY END-USER**
   1. Overview
   2. Hospitals
   3. Specialty clinics & oncology Centers
   4. Cancer Research Institute
2. **U.S. CANCER IMMUNOTHERAPY MARKET, BY DISTRIBUTION CHANNEL**

8.1 Overview

8.2 Hospital Pharmacies

8.3 Retail Pharmacies

8.4 Online Pharmacies

**9 U.S. CANCER IMMUNOTHERAPY MARKET COMPETITIVE LANDSCAPE**

9.1 Overview

9.2 Company Market Ranking

* 1. Key Development Strategies

1. **COMPANY PROFILES**

10.1 **Amgen Inc.**

### 10.1.1 Overview

### 10.1.2 Financial Performance

### 10.1.3 Product Outlook

### 10.1.4 Key Developments

10.2 **Bayer AG**

A close-up of hands holding a tablet and a pen

Description automatically generated 10.2.1 Overview

### 10.2.2 Financial Performance

### 10.2.3 Product Outlook

### 10.2.4 Key Developments

10.3 **Bristol-Myers Squibb**

### 10.3.1 Overview

### 10.3.2 Financial Performance

### 10.3.3 Product Outlook

### 10.3.4 Key Developments

10.4 **Eli Lilly and Company**

### 10.4.1 Overview

### 10.4.2 Financial Performance

### 10.4.3 Product Outlook

### 104.4 Key Developments

10.5 **F. hoffman La Roche Ltd.**

### 10.5.1 Overview

### 10.5.2 Financial Performance

### 10.5.3 Product Outlook

### 10.5.4 Key Developments

10.6 **Pfizer Inc**

### A close-up of hands holding a tablet and a pen Description automatically generated10.6.1 Overview

### 10.6.2 Financial Performance

### 10.6.3 Product Outlook

### 10.6.4 Key Development

10.7 **Novartis AG**

### 10.7.1 Overview

### 10.7.2 Financial Performance

### 10.7.3 Product Outlook

### 10.7.4 Key Developments

10.8 **Johnson & Johnson services**

### 10.8.1 Overview

### 10.8.2 Financial Performance

### 10.8.3 Product Outlook

### 10.8.4 Key Developments

10.9 **AstraZeneca**

### 10.9.1 Overview

### 10.9.2 Financial Performance

### 10.9.3 Product Outlook

### 10.9.4 Key Development

10.10 **Merck & Co.**

### A close-up of hands holding a tablet and a pen Description automatically generated10.10.1 Overview

### 10.10.2 Financial Performance

### 10.10.3 Product Outlook

### 10.10.4 Key Development

10.11 **AbbVie**

### 10.11.1Overview

### 10.11.2 Financial Performance

### 10.11.3 Product Outlook

### 10.11.4 Key Development

10.12 **Regeneron Pharmaceuticals**

### 10.12.1 Overview

### 10.12.2 Financial Performance

### 10.12.3 Product Outlook

### 10.12.4 Key Development

10.13 **Sanofi**

### 10.13.1 Overview

### 10.13.2 Financial Performance

### 10.13.3 Product Outlook

### 10.13.4 Key Development

10.14 **Immunocore**

### 10.14.1Overview

### 10.14.2 Financial Performance

### 10.14.3 Product Outlook

### 10.14.4 Key Development

10.15 **Adaptimmune Therapeutics**

### A close-up of hands holding a tablet and a pen Description automatically generated10.15.1 Overview

### 10.15.2 Financial Performance

### 10.15.3 Product Outlook

### 10.15.4 Key Development

1. **KEY DEVELOPMENTS**

11.1 Product Launches/Developments

11.2 Mergers and Acquisitions

11.3 Business Expansions

11.4 Partnerships and Collaborations

1. **Appendix**

12.1 Related Research